MC1R variants in relation to naevi in melanoma cases and controls: a pooled analysis from the M-SKIP project

for the M-SKIP Study Group

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)e135-e138
JournalJournal of the European Academy of Dermatology and Venereology
Volume35
Issue number2
DOIs
StatePublished - Feb 2021

Bibliographical note

Funding Information:
This work was supported by the Italian Association for Research on Cancer (grant AIRC MFAG 11831 to Sara Raimondi). For the Melanoma Susceptibility Study (PAK): National Cancer Institute (CA75434, CA80700, CA092428). For Genoa study (PG): AIRC IG 15460, Italian Ministry of Health RF‐2016‐02362288, and 5 x 1000 funds to Ospedale Policlinico San Martino. JL holds a Tier 1 Canada Research Chair. The research at the Melanoma Unit in Barcelona is partially funded by Spanish Fondo de Investigaciones Sanitarias grants PI15/00716, PI15/00956, PI18/00419 and PI18/01077; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co‐financed by European Development Regional Fund 'A way to achieve Europe' ERDF; AGAUR 2017_SGR_1134 of the Catalan Government, Spain; European Commission under the 6th Framework Programme, Contract No. LSHC‐CT‐2006‐018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; The National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115); a grant from 'Fundació La Marató TV3' 201331‐30, Catalonia, Spain; a grant from 'Fundación Científica de la Asociación Española Contra el Cáncer' GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. The Leeds UK study was funded by Cancer Research UK C588/A19167 and C588/A10721 and NIH CA83115.

Funding Information:
This work was supported by the Italian Association for Research on Cancer (grant AIRC MFAG 11831 to Sara Raimondi). For the Melanoma Susceptibility Study (PAK): National Cancer Institute (CA75434, CA80700, CA092428). For Genoa study (PG): AIRC IG 15460, Italian Ministry of Health RF-2016-02362288, and 5 x 1000 funds to Ospedale Policlinico San Martino. JL holds a Tier 1 Canada Research Chair. The research at the Melanoma Unit in Barcelona is partially funded by Spanish Fondo de Investigaciones Sanitarias grants PI15/00716, PI15/00956, PI18/00419 and PI18/01077; CIBER de Enfermedades Raras of the Instituto de Salud Carlos III, Spain, co-financed by European Development Regional Fund 'A way to achieve Europe' ERDF; AGAUR 2017_SGR_1134 of the Catalan Government, Spain; European Commission under the 6th Framework Programme, Contract No. LSHC-CT-2006-018702 (GenoMEL) and by the European Commission under the 7th Framework Programme, Diagnostics; The National Cancer Institute (NCI) of the US National Institute of Health (NIH) (CA83115); a grant from 'Fundaci? La Marat? TV3' 201331-30, Catalonia, Spain; a grant from 'Fundaci?n Cient?fica de la Asociaci?n Espa?ola Contra el C?ncer' GCB15152978SOEN, Spain, and CERCA Programme/Generalitat de Catalunya. Part of the work was carried out at the Esther Koplowitz Center, Barcelona. The Leeds UK study was funded by Cancer Research UK C588/A19167 and C588/A10721 and NIH CA83115.

Cite this